FAERS analysis finds distinct reported safety signals for newer seizure drugs

Real-world safety profiles of newer antiseizure medications: A pharmacovigilance study based on FDA Adverse Event Reporting System database.

Epileptic disorders : international epilepsy journal with videotape • • Highly Relevant
🤖

AI Summary

This pharmacovigilance study compared post-marketing adverse-event reports for four newer antiseizure medications, including cannabidiol (CBD). Researchers analyzed 13,763 reports submitted to the FDA Adverse Event Reporting System from 2016 through 2024. Across the medications, seizure-related events were frequently reported, and each drug had a distinct pattern: CBD was associated with gastrointestinal events, while the other medications showed different reported signals, including psychiatric, visual, and cardiac events.

The analysis also found that CBD-related gastrointestinal reports and fenfluramine-related cardiac reports showed dose-dependent patterns; children had higher reporting odds of seizure with CBD and brivaracetam, and polytherapy was associated with more reports of somnolence. These are patterns in spontaneous reports, not proof that a medication caused an event or a measure of how often events occur among users. Because the study relies on FAERS reports, it is vulnerable to underreporting and reporting biases; this abstract-based summary cannot establish causation or compare the actual risk of these medications in patients.

💡 Key Findings

1
In 13,763 FAERS reports, seizure-related adverse events were frequently reported across the four antiseizure medications studied.
High
90%
2
CBD reports showed a distinct pattern of gastrointestinal events, with a reported dose-dependent effect.
High
80%
3
Children had higher reporting odds of seizure with CBD and brivaracetam; these reporting patterns do not establish that the drugs caused seizures.
High
80%
4
The study identifies patterns in spontaneous adverse-event reports, but cannot establish causation or the incidence of adverse events among people taking these medications.
High
95%

📄 Original Abstract

OBJECTIVE: This study aimed to systematically evaluate and compare the post-marketing safety of four newer antiseizure medications (ASMs)-brivaracetam (BRV), cannabidiol (CBD), cenobamate (CNB), and fenfluramine (FFA). METHODS: A pharmacovigilance study was conducted using data from the FAERS database (Q1 2016-Q4 2024). Disproportionality analyses were performed to detect adverse event (AE) signals using three algorithms. Subgroup analyses were stratified by age, sex, reporter, and treatment strategy. We employed multivariable logistic regression, adjusted for covariates including age, sex, weight, dose, and concomitant medications, to validate associations between ASMs and specific AEs and to identify potential influencing factors. Bayesian network analysis was conducted to explore conditional dependencies among variables. Hospitalization risk was evaluated based on system organ classes. RESULTS: After data cleaning, 13 763 reports were included. We identified 308 positive preferred term (PT) signals. Seizure-related AEs were frequently reported. All four ASMs had the PT of seizure cluster, with each exhibiting distinct AE profiles: BRV with psychiatric disorders, CBD with gastrointestinal events, CNB with visual dysfunction, and FFA with valvular heart disease (VHD). Children had higher reporting odds of seizure with BRV and CBD, while reporting odds of FFA-related VHD were lower in children; polytherapy was associated with higher reporting odds of somnolence, and AE reporting patterns varied by reporter source. Both CBD-related gastrointestinal events and FFA-related cardiac events exhibited dose-dependent effects. Infection-related AEs were associated with higher odds of hospitalization for multiple ASMs. SIGNIFICANCE: This study comprehensively characterizes the safety profiles of newer ASMs and highlights the importance of tailored AE monitoring based on specific ASM and patient characteristics.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.